UPDATE 1-AstraZeneca flags cancer advances, silent on Pfizer bid talk
April 24, 2014 at 02:50 AM EDT
LONDON, April 24 (Reuters) - AstraZeneca highlighted progress with new cancer drugs that may revive its fortunes as it posted a 17 percent fall in core earnings per share on Thursday, reflecting patent losses on profitable older medicines.
